Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100466 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2PTGS1PTGS2FPR2 | |
| SCHEMBL1108540 | 0.87 | PGR (0.42) | ALDH1A1SMN1; SMN2KMT2APOLBL3MBTL1 | |
| SCHEMBL13500326 | 0.85 | ADAMTS4 (0.47) | ALDH1A1SMN1; SMN2PTGS2KMT2APOLB | |
| SCHEMBL7138393 | 0.83 | MMP9 (0.37) | ALDH1A1SMN1; SMN2MMP1ADAMTS4 | |
| SCHEMBL1108478 | 0.82 | MMP1 (0.41) | ALDH1A1SMN1; SMN2KMT2APOLBMMP1 | |
| SCHEMBL13127433 | 0.81 | MAPT (0.37) | ALDH1A1SMN1; SMN2KMT2APOLBIDO1 | |
| SCHEMBL1108539 | 0.81 | FFAR1 (0.42) | ALDH1A1SMN1; SMN2KMT2APOLBL3MBTL1 | |
| SCHEMBL1108570 | 0.81 | MMP9 (0.51) | ALDH1A1SMN1; SMN2MMP1ADAMTS4 | |
| SCHEMBL1108567 | 0.81 | MMP2 (0.43) | ALDH1A1SMN1; SMN2POLBMMP1 | |
| SCHEMBL1108533 | 0.80 | FFAR1 (0.41) | SMN1; SMN2MMP1ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885SMN1; SMN2 1262/4885PTGS1 124/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885SMN1; SMN2 1262/4885PTGS1 124/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | ALDH1A1 1172/4885SMN1; SMN2 1982/4885PTGS1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.